Details of Drug

Details of Drug

 Drug General Information (ID: D1701)
  Drug Name
Vismodegib
  Drug Type Small molecule
  Drug Synonymous
879085-55-9; GDC-0449; Erivedge; 2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide; Vismodegib (GDC-0449); HhAntag691; GDC0449; GDC 0449; UNII-25X868M3DS; CHEMBL473417; CHEBI:66903; 25X868M3DS; NSC755986; AK-77261; 2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide; C19H14Cl2N2O3S; 2-chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide; 2-chloro-n-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)benzamide; Erivedge (TN); Vismodegib (SHH inhibitor); Gdc-0449
    Click to Show/Hide
  Disease Class 2C32: Basal cell carcinoma; 2A00: Brain cancer
  Therapeutic Class Antineoplastics/Hedgehog Pathway Inhibitors
  Structure Could Not Find 2D Structure
3D Structure 2D Structure
  Formula C19H14Cl2N2O3S
  InChI 1S/C19H14Cl2N2O3S/c1-27(25,26)13-6-7-14(17(21)11-13)19(24)23-12-5-8-16(20)15(10-12)18-4-2-3-9-22-18/h2-11H,1H3,(H,23,24)
  InChIKey BPQMGSKTAYIVFO-UHFFFAOYSA-N
  Canonical SMILES CS(=O)(=O)C1=CC(=C(C=C1)C(=O)NC2=CC(=C(C=C2)Cl)C3=CC=CC=N3)Cl
  External Link
Pubchem ID 24776445
CAS Number 879085-55-9
CHEBI ID 66903
TTD ID D03EDQ
INTEDE ID DR1698
VARIDT ID DR00234

Drug-Drug Interaction Network
  Sunburst Graph
AM001  Affected gastrointestinal absorption
AM004  Affected intra/extra-hepatic metabolism
AM006  Pharmacodynamic additive effects
BM005  Altered gastric pH
BM017  CYP450 enzyme inhibition
BM109  Increased risk of other adverse reactions (Unspecific)
  Relation Graph
 Full list of drugs interacting with Vismodegib
      Affected gastrointestinal absorption
   Altered gastric pH Drug Num:  19
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0049
 
Aluminum hydroxide
 
AlH3O3
 
10176082 
Minor    Inter Info   
[6], [7], [8]
D0236
 
Calcium carbonate
 
CCaO3
 
10112 
Minor    Inter Info   
[6], [7], [8]
D0337
 
Cimetidine
 
C10H16N6S
 
2756 
Minor    Inter Info   
[6], [7], [8]
D0458
 
Dexlansoprazole
 
C16H14F3N3O2S
 
9578005 
Minor    Inter Info   
[6], [7], [8]
D0603
 
Esomeprazole
 
C17H19N3O3S
 
9568614 
Minor    Inter Info   
[6], [7], [8]
D0636
 
Famotidine
 
C8H15N7O2S3
 
5702160 
Minor    Inter Info   
[6], [7], [8]
D0892
 
Lansoprazole
 
C16H14F3N3O2S
 
3883 
Minor    Inter Info   
[6], [7], [8]
D0974
 
Magnesium oxide
 
MgO
 
14792 
Minor    Inter Info   
[6], [7], [8]
D1151
 
Nizatidine
 
C12H21N5O2S2
 
3033637 
Minor    Inter Info   
[6], [7], [8]
D1179
 
Omeprazole
 
C17H19N3O3S
 
4594 
Minor    Inter Info   
[6], [7], [8]
D1222
 
Pantoprazole
 
C16H15F2N3O4S
 
4679 
Minor    Inter Info   
[6], [7], [8]
D1373
 
Rabeprazole
 
C18H21N3O3S
 
5029 
Minor    Inter Info   
[6], [7], [8]
D1381
 
Ranitidine
 
C13H22N4O3S
 
3001055 
Minor    Inter Info   
[6], [7], [8]
D1382
 
Ranitidine (bismuth citrate)
 
C13H22N4O3S
 
3001055 
Minor    Inter Info   
[6], [7], [8]
D1480
 
Sodium bicarbonate
 
CHNaO3
 
516892 
Minor    Inter Info   
[6], [7], [8]
D0967
 
Magaldrate
 
AlHMgO5S+2
 
3086011 
Minor    Inter Info   
[6], [7], [8]
D0968
 
Magnesium carbonate
 
CMgO3
 
11029 
Minor    Inter Info   
[6], [7], [8]
D0973
 
Magnesium hydroxide
 
H2MgO2
 
14791 
Minor    Inter Info   
[6], [7], [8]
D1483
 
Sodium citrate
 
C6H5Na3O7
 
6224 
Minor    Inter Info   
[6], [7], [8]
      Affected intra/extra-hepatic metabolism
   CYP450 enzyme inhibition Drug Num:  2
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D1611
 
Torasemide
 
C16H20N4O3S
 
41781 
Moderate    Inter Info   
[1], [2], [3]
D1660
 
Tucatinib
 
C26H24N8O2
 
51039094 
Moderate    Inter Info   
[5]
      Pharmacodynamic additive effects
   Increased risk of other adverse reactions (Unspecific) Drug Num:  1
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0789
 
Idelalisib
 
C22H18FN7O
 
11625818 
Moderate    Inter Info   
[4]
References
1 Miners JO, Rees DLP, Valente L, Veronese ME, Birkett DJ "Human hepatic cytochrome p450 2c9 catalyzes the rate-limiting pathway of torsemide metabolism." J Pharmacol Exp Ther 272 (1995): 1076-81. [PMID: 7891318]
2 Product Information. Demedex (torsemide). Boehringer Mannheim, Gaithersburg, MD.
3 Vormfelde SV, Engelhardt S, Zirk A, et al. "CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide." Clin Pharmacol Ther 76 (2004): 557-66. [PMID: 15592327]
4 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
5 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
6 Cerner Multum, Inc. "Australian Product Information.".
7 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
8 Product Information. Erivedge (vismodegib). Genentech, South San Francisco, CA.